User: Guest  Login
Document type:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Article
Author(s):
Burges, A; Wimberger, P; Kümper, C; Gorbounova, V; Sommer, H; Schmalfeldt, B; Pfisterer, J; Lichinitser, M; Makhson, A; Moiseyenko, V; Lahr, A; Schulze, E; Jäger, M; Ströhlein, MA; Heiss, MM; Gottwald, T; Lindhofer, H; Kimmig, R
Title:
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Abstract:
PURPOSE: Malignant ascites in ovarian carcinoma patients is associated with poor prognosis and reduced quality of life. The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) enhances the antitumor activity by redirecting T cells and Fcgamma receptor I/III--positive accessory cells to the tumor. This multicenter phase I/II dose-escalating study investigated tolerability and efficacy of i.p. catumaxomab application in ovarian cancer patients with malignant ascites containing epithelial ce...    »
Journal title abbreviation:
Clin Cancer Res
Year:
2007
Journal volume:
13
Journal issue:
13
Pages contribution:
3899-905
Language:
eng
Print-ISSN:
1078-0432
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX